Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 20, Issue 3, 2002, Pages 804-810

  Trodella, Lucio ^a   Granone, Pierluigi ^a   Valente, Salvatore ^a   Turriziani, Adriana ^a   Macis, Giuseppe ^a   Corbo, Giuseppe M ^a   Margaritora, Stefano ^a   Cesario, Alfredo ^a   D'Angelillo, Rolando M ^a   Gualano, Gina ^a   Ramella, Sara ^a   Galetta, Domenico ^a   Cellini, Numa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 0036467639     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.3.804     Document Type: Article

References (40)

1. National survey of the pattern of care of carcinoma of the lung
2. The role of surgery in N2 lung cancer
3. Revisions in the international system for staging lung cancer
4. The importance of surgery to NSCLC with mediastinal lymph node metastasis
5. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83 to 12): Long-term results
6. Chemotherapy versus supportive care in advanced NSCLC: Results of meta-analysis of the literature
7. Treatment of superior sulcus tumor (Pancoast tumor)
8. Future directions in the treatment of non-small cell lung cancer
9. Effects of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer
10. Radiotherapy combined with low-dose cis-diammine-dichloroplatinum (II) (CDDP) in inoperable nonmetastatic non-small-cell lung cancer (NSCLC): A randomized three arms study of the EORTC Lung Cancer and Radiotherapy Cooperative Group
11. Neoadjuvant mitomycin C, cisplatin and infusion vinblastine in locally and regionally advanced non small cell lung cancer: Problems and progress from the prospective or long term follow-up
12. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III NSCLC: A phase II study of LCSG
13. Evaluation of an antitumor activity of gemcitabine (2′2′-difluoro -2′-deoxycytidine)
14. Preclinical in vivo activity of 2′2′ difluoro-deoxycytidine (gemcitabine) against human head and neck cancer
15. The influence of schedule and the dose of gemcitabine on the anti-tumor efficacy in experimental human cancer
16. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study
17. Single agent gemcitabine versus cisplatin-etoposide: Early results of randomized phase II in locally advanced or metastatic non-small cell lung cancer
18. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer
19. Radiosensitization of human tumor cells by gemcitabine in vitro
20. Gemcitabine: In vitro and in vivo evidence of its radiation sensitizing activity and studies using fluorine-19 magnetic resonance spectroscopy to determine the optimal dose schedule: Preclinical observations relevant to gemcitabine clinical trials
21. Metabolism of 2′,2′difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells
22. Radiosensitization of human solid tumor cell lines with gemcitabine
23. Radiosensitization of pancreatic cancer cells by 2′,2′difluorodeoxycytidine
24. Gemcitabine-mediate radiosensitization
25. Phase I trial of twice weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
26. Twice weekly gemcitabine and concurrent thoracic radiotherapy: A phase I/II study in patients with advanced non small cell lung cancer
27. Phase I trial of gemcitabine (G) and high dose thoracic radiation (RT) in stage III non small cell lung cancer
28. Gemcitabine plus radiotherapy for non-small cell lung cancer
29. Standardization of spirometry: 1987 Update
30. Gemcitabine in non-small cell lung cancer (NSCLC)
31. Gemcitabine and cisplatin as induction regimen for patients with biopsy proven stage IIIA N2 non-small cell lung cancer: A phase II trial of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)
32. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: Report by the Radiation Therapy Oncology Group
33. Current strategies for radiation therapy in non-small cell lung cancer
34. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer
35. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy: A Southwest Oncology Group trial
36. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung
37. Thoracic radiation therapy (TRT) for unresectable non-small cell lung cancer (NSCLC)
38. Target volume definition for three-dimensional conformal radiation therapy of lung cancer
39. Saturation of 2′2′ difluorodeoxycytidine 5′ triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
40. Gemcitabine weekly schedule better tolerated than a twice weekly schedule